Women and Lung Cancer Research and Preventive Services Act of 2025
Summary
HR2319 is a purely procedural authorization bill requiring HHS to conduct an interagency review and produce recommendations on lung cancer research and preventive services for women. It appropriates no funding, creates no programs, and contains no mandate that directly drives revenue for any public company. No actionable market signal exists.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2319 authorizes $0 — no appropriated funding, no grants, no procurement.
- 2.Bill only requires an HHS interagency review and recommendations; no programs created.
- 3.No public company is named or directly affected by any provision of this bill.
- 4.Senate passage and subsequent appropriations would be required before any market impact, likely years away.
- 5.Retail investors should ignore this bill — it is a policy placeholder with no near-term commercial implications.
Market Implications
No market implications. This bill moves no money, creates no contracts, and imposes no compliance costs. Any perceived 'healthcare sector' impact would be purely speculative. Investors should not allocate capital based on this legislation.
Full Analysis
On April 22, 2026, the Senate received HR2319 from the House, where it passed under suspension of the rules on April 21. The bill has been placed on the Senate Legislative Calendar. The bill's substance is limited: it directs the HHS Secretary (in consultation with Defense and VA Secretaries) to conduct an interagency review of lung cancer research gaps in women and underserved populations, and to produce recommendations on screening strategy and public education. The bill authorizes zero dollars — no funding is appropriated, no grants are created, and no procurement mandates exist. The text does not name any entity outside the federal government. The timeline for Senate floor action is uncertain; a companion bill (S1157) is also on the Senate calendar. Until either passes and the HHS review is completed and acted upon, no private-sector revenue impact can occur. No tickers merit inclusion because there is no causal chain — no mechanism in this bill obligates any private party to change behavior, incur costs, or receive revenue. Speculative association with lung cancer diagnostic or pharma companies (e.g., $LLY, $BMY, $VRTX) would be fabricated; the bill does not order, fund, or incentivize any private-sector activity. This is a data-gathering exercise with zero market consequences at this stage.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.